This study is looking at a medicine called Sutetinib Maleate for people with a type of lung cancer called Non-small Cell Lung Cancer (NSCLC) that has spread or is advanced. The medicine, Sutetinib, is being tested to see if it helps people with certain rare changes in the EGFR gene, which can make cancer cells grow. The study is for adults aged 18 and older who have had one or no chemotherapy treatments before. Participants must have a specific kind of EGFR mutation, like L861Q, G719X, or S768I. People who have used certain cancer treatments recently, or have serious health problems, can't enroll.

• Participants must attend multiple visits.
• Compensation may be provided for participation.
• Potential side effects of Sutetinib will be monitored.

Before joining, participants should consider the study duration and if they meet the health requirements. It's also important to ensure they are okay with regular visits and tests. Always talk to a doctor to understand the risks and benefits.